Acquired resistance to miriplatin in rat hepatoma AH109A/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosis

Miriplatin, a novel lipophilic platinum complex approved to treat hepatocellular carcinoma, is administered into the hepatic artery after suspension in an oily contrast medium. Little is known concerning the mechanism of acquired resistance to miriplatin. In this study, we established and characteri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology reports 2010-10, Vol.24 (4), p.1011-1018
Hauptverfasser:	HANADA, Mitsuharu, TAKASU, Hideo, KITAURA, Makoto
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - administration & dosage Apoptosis - genetics Biological and medical sciences Blotting, Western Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - therapy Cell Line, Tumor Cell Proliferation - drug effects Chemoembolization, Therapeutic - methods Cisplatin - pharmacology DNA Repair Enzymes - metabolism Drug Resistance, Neoplasm - genetics Gastroenterology. Liver. Pancreas. Abdomen Humans Liver Neoplasms - metabolism Liver Neoplasms - therapy Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Organoplatinum Compounds - administration & dosage Proto-Oncogene Proteins c-bcl-2 - biosynthesis Rats Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!